00389 2 3091 484
milan.risteski@zmc.mk
2022
Ekspert i licencuar mjeko-ligjor
2010
Specializim në onkologjinë klinike të rrezatimit
2000
Diplomuar në Fakultetin e Mjekësisë, Universiteti Kiril dhe Metodi, Shkup, Maqedoni
Licenca
2018 – në vazhdim
Специјалист по онкологија во Клиника Жан Митрев, Скопје, Македонија
Specialist onkolog në Klinikën Zhan Mitrev, Shkup, Maqedoni
2012 – 2017
Drejtor Mjekësor në Universitetin Klinik për Radioterapi dhe Onkologji (UKRO-së).
2002
Punonjës në Klinikën Universitare për Radioterapi dhe Onkologji (UKRO)
2000 – 2002
– Vullnetar në KARIL, Klinika Universitare për Alergologji Pulmonare
– Spitali i Specializuar i Qytetit për Gjinekologji dhe Obstetrikë, Cair
– Klinika Universitare për Sëmundje Infektive dhe Gjendje Febrile
– The mTOR pathway (International Neurology Congress of the Macedonian Neurology Society 2008)
– Ketogenic Diet as antiepileptic treatment (International Neurology Congress of the Macedonian Neurology Society 2008)
– Dietary treatment of refractory epilepsy in childhood (International Neurology Congress of the Macedonian Neurology Society 2008)
– TSC radiologic hallmarks (International Congress of the Macedonian Neuroimaging Society 2008)
– mTOR inhibition in the treatment of RCC and PNET (Experts Meeting of the Macedonian radiation oncology Society , 2009)
– Novel approaches to TSC treatment (II International Congress of Paediatric Neurology, Ohrid 2009)
– Clinical trial on therapeutic efficacy, tolerability and safety of Varumin in a combined treatment with polyvitamin – antioxidative therapy in patients with biologically (PCR) detected HPV infection of high-risk type (II International Congress of the Macedonian Society of Gynecology and Obstetrics, Skopje 2009)
– Pattern of cancerogenesis of high-risk HPV (II International Congress of the Macedonian Society of Gynecology and Obstetrics, Skopje 2009)
– Digestive tract cancer chemoprevention with Curcumin (Expert Meeting of the Macedonian Gastroenterohepathology Society, 2010)
– Reincarnation of Curcumin in modern evidence based medicine (Experts Meeting of the Macedonian radiation oncology Society, 2010)
– Stem cell treatment of autism – scientific challenge versus medical tourism (Macedonian Scientific Autism Association, 2nd of April, International Autism Day, 2011)
– Halliwick method of therapeutic swimming for children with cerebral palsy (International disability day, 3rd of December 2011, National Conference for disability)
– Importance of PI3K-S6K inhibition in cancer treatment and mechanism of action of Everolimus (Expert Meeting of the Macedonian radiation oncology Society, 9th of December, 2009)
– Inhibition of angiogenesis in ovarian cancer (III International Congress of the Macedonian Society of Gynecology and Obstetrics, Ohrid 2013)
– Mutational tree of NSCLC (V International Pulmology Congress of the Macedonian Respiratory Society, Ohrid 2012)
– Treatment of GBM with VEGF inhibitor – case report (Neurooncology Expert Forum Meeting 2012 December Luzern)
– Amplification of angiogenesis via thromboembolic mechanisms in cancer patients (Expert Meeting of the Macedonian Transfusion Society 2012)
– Importance of antioxidant supplementation during EBRT of primary brain tumours (Expert Meeting of the Macedonian Neurology Society, January 2012)
– Driver mutation patterns in malignant melanoma (Expert Meeting of MARO, 2013)
– Implementation on software guided gravimetric central chemocompounding at the UCRO (II Regional Congress of Supportive therapy and terminal care, Budva, Montenegro, 2014)
– Oncogenic signalling pathways (AROME Masterclass on molecular oncology, Skopje March 2015)
– Are we hitting the right target in TSC? (VII National Bulgarian Conference on rare diseases, Plovdiv, 2016)
– Principles of dual BRAF/MEK inhibition in BRAFmut metastatic melanoma (MAPRAS, Skopje 2016)
– Answered and unanswered questions in the medical cannabis treatment landscape in oncology (II MALMED Conference, Skopje 2016)
– Basics of cellular signalling (AROME ESO Meeting Skopje 2016)
– The challenge of second line treatment in mRCC – Axitinib (AROME ESO Meeting Skopje, 2016, Pfizer Symposium)
– RCC – how not to miss the treatment goal (2nd International Congress of the Macedonian Urologist Society, Skopje 2017)
– Systemic treatment options of melanoma (AROME Meeting, Budva 2017)
– Case report of PAX3-FOXO positive ARMS, poster presentation, (14th CEOC 2018, A best of ASCO Meeting Opatija)
– HIPEC and EPIC – early results, single institution experience, (Summer Oncology Forum of USTKA, Gdansk, Poland, September 2019)
– Intrathecal HER targeted treatment for HER+ BC in a highly sympthomatic patient, (56 Cancer week, Belgrade, Serbian Oncology Society, 6-9 November 2019, Belgrade)
– Tapentadol in pain treatment, online lecture, Pharmaceutical Chamber of Macedonia, 2021
– Urothelial and renal cell carcinoma challenges in 2021, 4th AROME ESO Joint Concensus Conference, 7-9 October 2021, Montenegro
– The story of medical cannabis – the good, the bad and the ugly, 7th Macedonian International Pharmacy Congress, 6-9 October 2022, Macedonia
– How useful are risk prediction SNP based tests for breast cancer among healthy general population, Future of treatment and care for breast cancer patients „FALENTY 2022” 2nd Polish – American Conference, November 17th – 19th, 2022, Warsaw, Poland
– Innovations in bladder cancer, 6th AROME – ESO Joint Concensus Conference, Budva, October 04th – 07th, 2023
– The clash of medical cannabis – from bench to bedside, Clinical Perspective for extract of medical cannabis (CBD/THC) use in pain treatment Workshop, 29th February 2024, Skopje
– Where immunology meets genetics – Genetic factors influencing immunotherapy response, COST Action: CA21135 – Modelling immunotherapy response and toxicity in cancer Conference, Skopje, 15th March 2024
ИЗРАБОТЕНИ ЕКСПЕРТСКИ МИСЛЕЊА:
– Cetuximab in HN cancer, reported to MALMED, 2014
– Cetuximab in CRC treatment, reported to MALMED 2014
– Pembrolizumab in cancer treatment, reported to MALMED 2016
– Sunitinib for RCC treatment, reported to MALMED 2015
– Axitinib for RCC treatment, reported to MALMED 2016
– Vinorelbine in the treatment of NSCLC and BC, reported to MALMED 2020
Angazhime të tjera profesionale:
– Kryehulumtues i studimeve klinike G1T28-03 dhe G1T28-04 për UKRO-në
– Nga 14.02.2012 deri më 20.06.2017, si Drejtor Mjekësor i UKRO-së, kam zbatuar:
Akreditimi kombëtar i UKRO – Në vitin 2013 krijova Protokollet për Menaxhimin e Krizave në pikën kufitare Bogorodicë në kufirin maqedono-grek në lidhje me transferimin e pacientëve kritikë midis spitaleve në Gjevgjeli dhe Polikastro, në kuadër të Projektit të Bashkëpunimit Ndërkufitar të BE-së për Maqedoninë dhe Greqinë.
A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries, Yazid Belkacemi, Noemie Grellier, Sahar Ghith, Kamel Debbi, Gabriele Coraggio, Adda Bounedjar, Redouane Samlali, Pauletta G. Tsoutsou, Mahmut Ozsahin, Marie-PierreChauvet, Sedat Turkan, Hamouda Boussen, Abraham Kuten, Dusanka Tesanovic, Hassan Errihani, Farouk Benna, Kamel Bouzid, Ahmed Idbaih, Karima Mokhtari, Lazar Popovic, Jean-Philippe Spano, Jean-Pierre Lotz, Aziz Cherif, Hahn To, Vladimir Kovcin, Oliver Arsovski, Semir Beslija, Radan Dzodic, Ivan Markovic, Suzana Vasovic, Liljana Stamatovic, Davorin Radosavljevic, Sinisa Radulovic, Damir Vrbanec, Souha Sahraoui, Nino Vasev, Igor Stojkovski, Milan Risteski, Salvador Villa` Freixa, Marco Krengli, Nina Radosevic, Giorgio Mustacchi, Mladen Filipovic, Khaldoun Kerrou, Alphonse G. Taghian, Vladimir Todorovic, Fady Geara, Joseph Gligorov, European Journal of Cancer, Vol 135,P130-146, DOI: https://doi.org/10.1016/ejca.2020.05.015
– MARO (Macedonian Association of radiotherapy and oncology)
– AROME (Association of Radiotherapy and Oncology of the Mediterranean area)
– ESO (European School of oncology)
– ESMO (European Society of medical oncology)
– ESTRO (European Society for Radiotherapy and Oncology)
Anglisht
Serbisht
Кroatisht